Induction and maintenance phase NMA INF 5 mg/kg
| Analysis | Comparator | Comparator vs PBO | SUCRA* (%) | |
| OR, median (95%CrI) | ||||
| Clinical response | Clinical remission | |||
| Induction phase | TNFi-naïve subgroup | |||
| PBO | 0.8 | |||
| TOF 10 mg BID | 2.66(1.56to4.76) | 2.99(1.67to5.45) | 62.1 | |
| INF 5 mg/kg | 3.78(2.46to6.1) | 4.28(2.73to6.91) | 90.7 | |
| ADA 160/80/40 mg† | 1.75(1.07to2.82) | 1.9(1.09to3.21) | 28.4 | |
| GOL 200/100 mg‡ | 2.4(1.11to5.31) | 2.69(1.13to6) | 53.7 | |
| VED 300 mg§ | 2.74(1.4to5.36) | 3.08(1.48to6.09) | 64.2 | |
| TNFi-exposed subgroup | ||||
| PBO | 17.3 | |||
| TOF 10 mg BID | 4.28(1.27to18.59) | 5.61(1.36to24.53) | 92.9 | |
| ADA 160/80/40 mg† | 1.43 (0.11 to 13.16) | 1.57 (0.05 to 17.65) | 42.4 | |
| VED 300 mg§ | 1.55 (0.27 to 7.24) | 1.74 (0.17 to 10.01) | 47.4 | |
| Maintenance phase | TNFi-naïve subgroup | |||
| PBO | 9.2 | |||
| TOF 5 mg BID | 4.58 (0.42 to 78.74) | 4.71 (0.39 to 65.66) | 68.2 | |
| TOF 10 mg BID | 6.03 (0.56 to 117.98) | 6.14 (0.53 to 94.07) | 78.0 | |
| INF 5 mg/kg | 2.27 (0.17 to 30.23) | 2.34 (0.15 to 27.67) | 42.0 | |
| ADA 40 mg Q2W | 1.82 (0.32 to 10.32) | 1.86 (0.29 to 10.28) | 32.5 | |
| GOL 50 mg | 2.31 (0.26 to 27.57) | 2.38 (0.23 to 25.65) | 42.4 | |
| GOL 100 mg | 3.07 (0.65 to 23.21) | 3.17 (0.63 to 21.72) | 55.5 | |
| VED 300 mg Q8W | 3.78 (0.63, 23.84) | 3.89 (0.61 to 22.29) | 62.7 | |
| VED 300 mg Q4W | 3.55 (0.35 to 44.46) | 3.66 (0.32 to 38.93) | 59.4 | |
| TNFi-exposed subgroup | ||||
| PBO | 0.8 | |||
| TOF 5 mg BID | 4.53(2.1to22.23) | 4.7(2.12to26.64) | 47.8 | |
| TOF 10 mg BID | 8.66(3.87to65.79) | 8.98(3.91to80.19) | 87.1 | |
| ADA 40 mg Q2W | 2.97 (0.86 to 17.51) | 3.07 (0.86 to 20.36) | 33.4 | |
| VED 300 mg Q8W | 6.51(2.45to46.58) | 6.78(2.49to56.15) | 69.6 | |
| VED 300 mg Q4W | 5.74(1.91to41.39) | 5.97(1.94to49.09) | 61.3 | |
Bold font indicates a significant result, shown by CrIs which exclude the null value.
*SUCRA is a numeric assessment of the overall ranking of treatments. SUCRA values for each treatment range from 0% to 100%. The higher the SUCRA value, the higher the likelihood that a therapy is the most efficacious or one of the most efficacious treatment; however, SUCRA values are not probabilities of a therapy being the most efficacious.
†160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6.
‡200 mg at week 0, 100 mg at week 2.
§At weeks 0 and 2.
ADA, adalimumab;BID, twice daily; CrI, credible interval; GOL, golimumab; INF, infliximab;NMA, network meta-analysis; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; Q8W, every 8 weeks; SUCRA, surface under cumulative ranking curve; TNFi, tumour necrosis factor inhibitor; TOF, tofacitinib; VED, vedolizumab.